Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chabiotech | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩640.9B | -53.3x | -4.39 | ₩11,710 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GC Cell | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩338.11B | -98.9x | -1.52 | ₩22,950 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Labgenomics | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩178.55B | -8.7x | 0.01 | ₩2,420 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
DT CRO | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩80.33B | 34.3x | ₩6,400 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Dreamcis | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩68.3B | 15.3x | 0.07 | ₩2,910 | 1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Biotoxtech | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩48.03B | -11.3x | -0.7 | ₩3,055 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
U2Bio | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩35.27B | 67.8x | ₩3,240 | 3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
SLS Bio | KOSDAQ | Healthcare | Healthcare Providers & Services | ₩21.93B | 28.2x | ₩1,622 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |